PL2717692T3 - Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych - Google Patents

Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych

Info

Publication number
PL2717692T3
PL2717692T3 PL12796691T PL12796691T PL2717692T3 PL 2717692 T3 PL2717692 T3 PL 2717692T3 PL 12796691 T PL12796691 T PL 12796691T PL 12796691 T PL12796691 T PL 12796691T PL 2717692 T3 PL2717692 T3 PL 2717692T3
Authority
PL
Poland
Prior art keywords
fiberatal
tetrahydrocannabinol
owe
diseases
acids
Prior art date
Application number
PL12796691T
Other languages
English (en)
Inventor
Robert B. Zurier
Enrico Selvi
Original Assignee
Corbus Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corbus Pharmaceuticals, Inc. filed Critical Corbus Pharmaceuticals, Inc.
Publication of PL2717692T3 publication Critical patent/PL2717692T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL12796691T 2011-06-04 2012-06-01 Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych PL2717692T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161493435P 2011-06-04 2011-06-04
US13/485,044 US20120309820A1 (en) 2011-06-04 2012-05-31 Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids
EP12796691.9A EP2717692B1 (en) 2011-06-04 2012-06-01 Tetrahydrocannabinol-11-oic acids for use in treating fibrotic diseases
PCT/US2012/040380 WO2012170290A1 (en) 2011-06-04 2012-06-01 Methods of treating fibrotic diseases using tetrahydrocannabinol-11-oic acids

Publications (1)

Publication Number Publication Date
PL2717692T3 true PL2717692T3 (pl) 2020-06-15

Family

ID=47262154

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12796691T PL2717692T3 (pl) 2011-06-04 2012-06-01 Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych

Country Status (8)

Country Link
US (3) US20120309820A1 (pl)
EP (2) EP3620211A1 (pl)
DK (1) DK2717692T3 (pl)
ES (1) ES2753639T3 (pl)
HU (1) HUE047419T2 (pl)
PL (1) PL2717692T3 (pl)
PT (1) PT2717692T (pl)
WO (1) WO2012170290A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015019180A8 (pt) 2013-02-12 2018-01-30 Corbus Pharmaceuticals Inc ácidos tetrahidrocanabinol-11-óicos ultrapuros
JP6307290B2 (ja) * 2013-03-06 2018-04-04 東京応化工業株式会社 レジスト組成物、レジストパターン形成方法
EP3160445B1 (en) 2014-06-26 2021-10-20 Island Breeze Systems Ca, LLC Mdi related products and methods of use
CA3010861A1 (en) * 2016-01-08 2017-07-13 Colonaryconcepts Llc Food based delivery of cannabinoids
WO2017149392A1 (en) * 2016-03-04 2017-09-08 Sharon Anavi-Goffer Self-emulsifying compositions of cb2 receptor modulators
JP2019515927A (ja) * 2016-04-29 2019-06-13 コーバス ファーマシューティカルズ インク． 感染症の処置のための方法
AU2019278992A1 (en) * 2018-05-31 2020-12-17 Corbus Pharmaceuticals Inc. Cannabinoids and uses thereof
EP3823610A4 (en) * 2018-07-17 2022-08-31 The Regents of the University of California METHODS OF TREATMENT OF KIDNEY DISEASE
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
JP2023520727A (ja) 2020-04-08 2023-05-18 ミッション セラピューティクス リミティド Ｕｓｐ３０阻害剤として活性を有するｎ－シアノピロリジン
IL298526A (en) 2020-05-28 2023-01-01 Mission Therapeutics Ltd N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction
US20230303547A1 (en) 2020-06-04 2023-09-28 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
DK4161929T3 (da) 2020-06-08 2025-08-18 Mission Therapeutics Ltd 1-(5-(2-cyanopyridin-4-yl)oxazol-2-carbonyl)-4-methylhexahydropyrrolo[3,4-b]pyrrol-5(1h)-carbonitril som usp30-hæmmer til anvendelse i behandling af mitokondriedysfunktion, cancer og fibrose
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
JP2024544660A (ja) 2021-12-01 2024-12-03 ミッション セラピューティクス リミティド Ｕｓｐ３０阻害剤としての活性を有する置換ｎ－シアノピロリジン
GB202408928D0 (en) 2024-06-21 2024-08-07 Mission Therapeutics Ltd Novel compounds
GB202411060D0 (en) 2024-07-29 2024-09-11 Mission Therapeutics Ltd Novel compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507767B2 (en) * 2001-02-08 2009-03-24 Schering Corporation Cannabinoid receptor ligands
US20040186166A1 (en) * 2002-12-19 2004-09-23 Burstein Sumner H. Cannabinoid analogs as peroxisome proliferator activated nuclear receptor gamma activators
US8058227B2 (en) * 2006-10-03 2011-11-15 Medical University Of South Carolina Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD
US8877188B2 (en) * 2010-05-04 2014-11-04 The Brigham And Women's Hospital, Inc. Detection and treatment of non-dermal fibrosis

Also Published As

Publication number Publication date
EP2717692A1 (en) 2014-04-16
PT2717692T (pt) 2019-11-18
WO2012170290A1 (en) 2012-12-13
US20120309820A1 (en) 2012-12-06
DK2717692T3 (da) 2019-11-11
ES2753639T3 (es) 2020-04-13
EP3620211A1 (en) 2020-03-11
EP2717692B1 (en) 2019-08-07
US20160367518A1 (en) 2016-12-22
HUE047419T2 (hu) 2020-04-28
EP2717692A4 (en) 2015-02-18
US20180116999A1 (en) 2018-05-03

Similar Documents

Publication Publication Date Title
PL2717692T3 (pl) Kwasy tetrahydrokannabinol-11-owe do stosowania w leczeniu chorób zwłóknieniowych
LTPA2020510I1 (lt) Pakeistieji 4-fenil-piridinai, skirti su NK-receptoriumi susijusių ligų gydymui
IL285843A (en) Ibrutinib for use in the treatment of chronic graft versus host disease
IL235512B (en) Phenylbenzamide derivatives for use in treating diseases mediated by aquaporin
HUE043171T2 (hu) Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek
IL232256A0 (en) Novel purine derivatives and their use in the treatment of disease
IL229474B (en) Cannabinoids for use in the treatment of neuropathic pain
IL228649B (en) Immunogenic compositions for use in therapy
DK2919796T3 (da) Brug af akkermansia til behandling af stofskiftesygdomme
HUE046239T2 (hu) Zsírsav keverékek gyulladásos megbetegedések kezelésében való alkalmazásra
PL2718434T3 (pl) Kompozycje i sposoby leczenia choroby trzewnej
GB2496688B (en) Tetrahydrocannabivarin for use in the treatment of intestinal inflammatory diseases
EP2695154A4 (en) PROVIDING A COMPUTER-BASED LANGUAGE THERAPY
EP2718255A4 (en) QUINONE COMPOUNDS FOR THE TREATMENT OF APE1 MEDIATION DISEASES
IL234606B (en) Novel methods and composition for treatment of disease
IL229081A0 (en) Isoxazolines as therapeutic agents
ZA201500547B (en) Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
CO6880064A2 (es) Métodos terapéuticos
PL3447070T3 (pl) Związki do leczenia blokady mielinizacji w chorobach związanych z ekspresją białka otoczki herv-w
ITRM20120530A1 (it) Compounds for use in the treatment of parasitic diseases
GB2515440B (en) Vesicular Formulations for use in the treatment of Rosacea
HRP20180011T1 (hr) Spojevi za uporabu u liječenju filariaza
GB201114289D0 (en) Flurbiprofen and related compounds for the treatment of skin diseases
IL239078A0 (en) Protein for use in the treatment of eye diseases
DK2694056T3 (da) Terapeutisk behandling